Eplerenone for the treatment of cardiovascular disorders

Abstract

The clinical utility and ultimately guideline recommendations for aldosterone receptor-blocking agents in cardiovascular disorders is clearly mentioned by a number of major clinical outcome trials. This article reviews the pharmacology, clinical efficacy and safety of the two currently available receptor blocking agents: spironolactone and eplerenone. The potential utility of eplerenone and other mineralocorticoid receptor agents beyond current clinical indications will also be examined.

Keywords::

• aldosterone receptor-blocking agents
• cardiovascular disorders
• eplerenone
• heart failure
• mineralocorticoid receptor
• treatment

Financial & competing interests disclosure

H Krum has served on the steering committee of the EMPHASIS HF trials. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.